therapeutic

Aurora Cannabis Expands Again in a 2.5 Billion Deal with MedReleaf

Aurora Cannabis Expands Again in a 2.5 Billion Deal with MedReleaf

Just months after  buying out CanniMed Therapeutics for C$1.23 billion ($1 billion U.S.D.)  making it the largest merger in Canada at the time, Aurora Cannabis Inc (TSE: ACB) announced on Monday that it will buy rival MedReleaf Corp (..

Juno Shares Surge on Celgene’s $9 Billion Acquisition

Juno Shares Surge on Celgene’s $9 Billion Acquisition

Juno Therapeutics Inc. (NASDAQ: JUNO) shares continued to surge on Monday after Celgene Corp. (NASDAQ: CELG) had entered into an agreement to acquire Juno for a total of $9 billion or $87 per share. Juno shares rose 27 percent during Monday&rsq..

Spark Therapeutics offers to cure blindness for $850,000

Spark Therapeutics offers to cure blindness for $850,000

Spark Therapeutics Inc (NASDAQ: ONCE) Luxturna, the first gene therapy in the U.S., has been approved by the Food and Drug Administration. The gene therapy is intended to treat a rare, inherited retinal disease that could possibly cause blindness. U..

Revance Therapeutics Shares Jumped After Positive Top-Line Results From Phase 3 Trial

Revance Therapeutics Shares Jumped After Positive Top-Line Results From Phase 3 Trial

Revance Therapeutics Inc (NASDAQ: RVNC) is a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions. On Tuesday shares of the Revance jumped about 10% a after the company announced its n..

Insys co-founder Arrested on alleged Nationwide Opioid Scheme

Insys co-founder Arrested on alleged Nationwide Opioid Scheme

Co-Founder of Insys Therapeutics Inc. (NASDAQ: INSY) was arrested on Thursday by federal agents and charged with bribery, racketeering, and fraud to cause the illegal distribution of Fentanyl.John Kapoor was taken into custody in Phoenix, Arizona. K..

Alnylam Pharmaceuticals Stock Jumps After Positive Phase 3 Trial Results

Alnylam Pharmaceuticals Stock Jumps After Positive Phase 3 Trial Results

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) shares jumped more than 40% after the pharma company, together with Sanofi Genzyme, the specialty care global business unit of Sanofi, announced that the APOLLO Phase 3 study of patisiran, an investigatio..